Open AccessLong‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
Author(s) -
Winkelmann Nina,
Schwarz Michaela,
Hildebrandt Bert,
Henke Oliver,
Bullinger Lars,
Na IlKang,
Stintzing Sebastian,
le Coutre Philipp
Publication year - 2022
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.502
Subject(s) - medicine , myeloid leukemia , colorectal cancer , tyrosine kinase inhibitor , oncology , tyrosine kinase , cancer , leukemia , gastroenterology , receptor
In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety‐one patients with CML and 76 controls were included and in total 4 (4.4%) secondary malignancies were found in patients and 8 (10.5%) in controls. The risk for secondary malignancies was not significantly elevated for CML patients ( p = 0.141). Two (2.2%) CML patients developed colorectal cancer compared to 4 (5.3%) in the reference group. A higher risk for CML patients for colorectal cancer could not be found ( p = 0.414).